跳转至内容
Merck
CN

GF58573648

powder, 1g, max. particle size 500 micron, 99.9%

别名:

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
Lu
CAS号:
分子量:
174.97
MDL编号:
UNSPSC代码:
11101711
PubChem化学物质编号:
NACRES:
NA.23

方案

99.9%

表单

powder

制造商/商品名称

Goodfellow 585-736-48

电阻率

54 μΩ-cm, 20°C

粒径

500 μm

沸点

3402 °C (lit.)

mp

1663 °C (lit.)

密度

9.84 g/mL at 25 °C (lit.)

SMILES字符串

[Lu]

InChI

1S/Lu

InChI key

OHSVLFRHMCKCQY-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

For updated SDS information please visit www.goodfellow.com.

法律信息

Product of Goodfellow

象形图

Flame

警示用语:

Danger

危险声明

危险分类

Flam. Sol. 1

储存分类代码

4.1B - Flammable solid hazardous materials

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

R O Perez et al.
Techniques in coloproctology, 18(8), 699-708 (2014-02-11)
Molecular imaging using positron emission tomography/computerized tomography (PET/CT) may add relevant incremental diagnostic information to standard structural cross-sectional imaging. Such information may allow identification of patients with rectal cancer that are more likely to develop complete tumor regression after neoadjuvant
B L R Kam et al.
European journal of nuclear medicine and molecular imaging, 39 Suppl 1, S103-S112 (2012-03-06)
Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The
S Panigone et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 50(4), 310-321 (2006-10-18)
Optimization of therapy for individual patients remains a goal of clinical practice. Radionuclide imaging can identify those patients who may benefit from subsequent targeted therapy by providing regional information on the distribution of the target. An ideal situation may be
Constantin Lapa et al.
Nuclear medicine and biology, 42(4), 349-354 (2015-01-18)
Peptide receptor radionuclide therapy (PRRT) is a treatment option for both iodine-refractory differentiated and advanced medullary thyroid cancer (TC). It requires over-expression of somatostatin receptor subtype II (SSTR) that can be non-invasively assessed by positron emission tomography (PET). Assessment of
Alin Chirindel et al.
AJR. American journal of roentgenology, 204(5), 1093-1099 (2015-04-24)
The purpose of this study is to evaluate the performance of PET-derived parameters as prognostic markers for overall survival (OS) and progression-free survival (PFS) outcome in patients with pancreatic adenocarcinoma. We conducted a retrospective study of 106 patients (62 men

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门